A Comparative Study of Statistical Methods to Assess Dilutional Similarity - The four parameter logistic model is a better control method than the dilution effect statistic - BioPharm International


A Comparative Study of Statistical Methods to Assess Dilutional Similarity
The four parameter logistic model is a better control method than the dilution effect statistic

BioPharm International

Figure 3. Intact vs. Degraded RNA Divergence at most concentrations. Dilutional similarity rejected by F-test. Barely accepted by DE test.
These results demonstrated that the DE statistics did not assess accurately the parallelism between the test sample and the reference standard in that there were questionable acceptances.


Figure 4. Agilent 2100 Bioanalyzer Data of a High Quality, Eukaryotic, Total RNA Sample Dilutional similarity accepted.
The DE measure assesses the parallelism at the linear part of the standard curve. It is a practical measurement that might be a solution for the differences in matrix, such as different initial concentrations tested and different sets of concentrations of references and test samples tested in the assay. However, fitting a logistic response and using only the linear part might lead to a biased estimate during assay development. The use of DE measure in parallel-line assay with the appropriate test design might be more appropriate.

Figure 5. Different Types of Genomic DNA Contamination In Total RNA Preparations Both tests reject dilutional similarity.
F-statistics are very sensitive to the differences in matrix and should not be used when the reference and test sample are not tested with the same concentrations. Set the acceptance criteria for parallelism according to the stage during test development. The critical value is determined by the alpha level, which is the rejection rate assuming parallelism. Typical values for alpha are 5%, 1% or 0.1%. In practice, assays are rejected too frequently for nonparallelism when alpha is 5%, but it is difficult to see the nonparallelism. One could set the alpha level to 1% or 0.1% at the beginning of the test development and increase alpha to 5% after all the parameters are under control.

Departure from dilutional similarity can be interpreted as evidence that the groups of organisms are not comparable or the preparations do not contain the same active compound. Failure of the parallelism test is often the first evidence that a product is not stable. F- statistics can be used for full curves analysis to test for parallelism (but we recommend you test that the asymptotes have not changed).

Use DE with caution. As DE uses only the slopes of the test sample and reference standard, conduct a data transformation and a parallel line analysis.

Eloi P.Kpamegan,Ph.D.,MSF, Manager Biostatistics Unit, Global Clinical Immunology, North American Analytical Science and Assay Development Sanofi Pasteur, One Discovery Drive, Swiftwater, PA 18370 570.839.4659,Fax:570.895.2972,


1. Reeve R. Two statistical methods for estimating relative potency of bioassays. Biopharm Int. 2000 July; 13(7):54-60.

2. Emmens CW. The dose response relationship for certain principles of the pituitary gland, and of the serum and urine of pregnancy. Journal of Endocr. 1940; 2:194-225.

3. Finney DJ. Response curves for radioimmunoassay. Clinical Chemistry 1983; 29:1562-1566.

4. Finney DJ. Statistical methods in biological assay, 3rd ed. London: Griffin; 1978.

5. Klein J, Capen R, Mancinelli R, Robinett R, Pietrobon FPJ, Quinn J, Schofield T. Validation of assays for use with combination vaccines, Biologicals 1999; 27:35-41.

6. Schofield T. Assay Validation. In: Encyclopedia of Biopharmaceutical Statistics. New York: Marcel Dekker 2000; p. 21–30.

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here